September 2022 News
Our recent progress with the characterization of NF-L antibodies allow us to generate a novel and useful new reagent. This is our NF-L biomarker assay standard PROT-r-NF-L-Stan. This is a small recombinant protein which includes the epitopes for the two antibodies used in the NF-LIGHT™ and Quanterix Simoa™ NF-L biomarker assays. The recombinant construct is engineered to include tryptophan residues which allow accurate spectrophotometric quantitation of protein concentration by measuring optical density at a wavelength of 280nm. The generation of this product is based on the discoveries outlined in our recent BioRχiv article, see www.biorxiv.org/content/10.1101/2022.08.27.504533v1.
Our antibodies continue to be useful throughout the world! For example our mouse monoclonal antibody to adenylcyclase type III MCA-1A12, a convenient and key marker of neuronal cilia, was employed as part of a very high profile publication from the Janelia Research Campus, Howard Hughes Medical Institute, which provides evidence that neuronal cilia form functional synapses with serotonergic axons, see Cell 185:3390-3407 (2022). See a description of this work on the Janelia website here.
